Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events.

CONCLUSIONS AND SIGNIFICANCE: Patients with CR status may continue to show a response or durable disease control even after stopping therapy due to an irAE.
PMID: 32808841 [PubMed - as supplied by publisher]

Source: Acta Oto-Laryngologica - August 17, 2020 Category: ENT & OMF Authors: Yasumatsu R, Matsuo M, Wakasaki T, Masuda M, Takeuchi T, Manako T, Jiromaru R, Uchi R, Hashimoto K, Nakagawa T Tags: Acta Otolaryngol Source Type: research